Aromatase Inhibitor News and Research RSS Feed - Aromatase Inhibitor News and Research

Aromatase Inhibitors are drugs that prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy for postmenopausal women who have hormone-dependent breast cancer.
Telephone-based weight loss intervention is effective in breast cancer treatments

Telephone-based weight loss intervention is effective in breast cancer treatments

A series of simple telephone calls can make a profound difference in helping women to meet their treatment goals for breast cancer, according to a randomized trial of women who are also obese, published online today in Journal of Clinical Oncology by Dr. Pamela Goodwin of Mount Sinai Hospital and the Lunenfeld-Tanenbaum Research Institute. [More]
GRU combines with national Cooperative to improve treatment of reproductive health

GRU combines with national Cooperative to improve treatment of reproductive health

Georgia Regents University has joined the national Cooperative Multicenter Reproductive Medicine Network designed to enable large clinical trials that improve the diagnosis and treatment of reproductive health issues such as male and female infertility. [More]
Acupuncture treatments may help alleviate side effects of breast cancer drugs

Acupuncture treatments may help alleviate side effects of breast cancer drugs

A new analysis has found that both real and sham acupuncture treatments may help alleviate side effects of drugs commonly used to treat breast cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help clinicians improve care for cancer patients. The results also raise the question of whether sham acupuncture is truly inert or may, like real acupuncture, have beneficial effects. [More]
Breast cancer patients experience fewer side effects on using aromatase inhibitor with sham acupuncture

Breast cancer patients experience fewer side effects on using aromatase inhibitor with sham acupuncture

​Breast cancer patients experience fewer side effects while being treated with a widely used drug called an aromatase inhibitor when they get acupuncture - either the real treatment or a "sham" procedure, according to a new study led by researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center. [More]
Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. [More]
Breast cancer survivors taking AIs may experience reduction in joint pain on exercising

Breast cancer survivors taking AIs may experience reduction in joint pain on exercising

Breast cancer survivors taking aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane experienced a reduction in joint pain if they exercised while on treatment, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. [More]
New research shows that the brain can produce and release estrogen

New research shows that the brain can produce and release estrogen

A University of Wisconsin-Madison research team reports today that the brain can produce and release estrogen - a discovery that may lead to a better understanding of hormonal changes observed from before birth throughout the entire aging process. [More]
Gene sequencing reveals mutations in estrogen receptor

Gene sequencing reveals mutations in estrogen receptor

Researchers at the University of Michigan Comprehensive Cancer Center have identified a type of mutation that develops after breast cancer patients take anti-estrogen therapies. The mutations explain one reason why patients often become resistant to this therapy. [More]
Self-directed walking program shows promise in easing joint stiffness in older breast cancer patients

Self-directed walking program shows promise in easing joint stiffness in older breast cancer patients

A self-directed walking program shows promise in easing joint stiffness in older women who experienced these symptoms while taking aromatase inhibitor therapy for breast cancer, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego. [More]
Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Amgen today announced that it will present data from several romosozumab and Prolia® (denosumab) studies at the American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting in Baltimore from Oct. 4-7, 2013. [More]
FDA grants Breakthrough Therapy designation to Syndax's entinostat for ER+ breast cancer

FDA grants Breakthrough Therapy designation to Syndax's entinostat for ER+ breast cancer

Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has progressed following non-steroidal aromatase inhibitor therapy. [More]
Physicians discuss use of new guidelines on aromatase inhibitor to prevent breast cancer

Physicians discuss use of new guidelines on aromatase inhibitor to prevent breast cancer

The American Society of Clinical Oncology (ASCO) is now recommending that physicians discuss use of the aromatase inhibitor exemestane (Aromasin) to prevent breast cancer in at-risk postmenopausal women. [More]
Biomarker indicates which women are at risk for breast cancer recurrence after tamoxifen

Biomarker indicates which women are at risk for breast cancer recurrence after tamoxifen

A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment. [More]
Gabriel Hortobagyi recognized with AACR-MICR Jane Cooke Wright Lectureship

Gabriel Hortobagyi recognized with AACR-MICR Jane Cooke Wright Lectureship

Gabriel Hortobagyi, M.D., professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, will receive the Jane Cooke Wright Lectureship from the American Association for Cancer Research and its Minorities in Cancer Research membership group. [More]
New study shows some women don't stick to recommended treatment for breast cancer

New study shows some women don't stick to recommended treatment for breast cancer

One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course, according to a new study led by University of Michigan Comprehensive Cancer Center researchers. [More]

Genetic differences in enzyme CYP2D6 play a key role in effectiveness of tamoxifen for breast cancer

For nearly a decade, breast cancer researchers studying the hormone therapy tamoxifen have been divided as to whether genetic differences in a liver enzyme affect the drug's effectiveness and the likelihood breast cancer will recur. [More]
ATLAS holds up 10-year tamoxifen regime

ATLAS holds up 10-year tamoxifen regime

Results from the ATLAS study indicate that women with estrogen receptor-positive breast cancer should consider taking tamoxifen for up to 10 years after diagnosis. [More]
Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases. [More]
ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women. [More]
Combination therapy delays progression for metastatic breast cancer patients

Combination therapy delays progression for metastatic breast cancer patients

Phase III trial results show that a combination of the aromatase inhibitor anastrozole and fulvestrant, an analog of estradiol that downgrades the estrogen receptor, is superior to anastrozole alone in prolonging progression-free survival in patients with metastatic breast cancer. [More]